JeNaCell produces biotechnologically generated nanocellulose (BNC) in an IP protected, continuous and automated production process: high quality innovative products for applications in medicine, cosmetics and more.

Press releases

2. August 2021

Successful exit for High-Tech Gründerfonds – HTGF fund investor Evonik acquires biotech company JeNaCell

Acquisition of JeNaCell expands Evonik’s portfolio of biomaterials used in medical technologyJeNaCell to realize full potential of its innovative technology and further expand its technology portfolio with Evonik’s supportHigh-Tech Gründerfonds (HTGF) financed the seed round in 2012 together with the Foundation for Technology, Innovation and Research Thuringia (STIFT)bm|t acquired stake in JeNaCell in 2015 together with Sparkasse Jena-Saale-Holzland and HTGF fund investor Evonik Venture
9. July 2015
Additional financing for JeNaCell: Investors once again back platform technology for the production of high-tech bio-material
The Jena biotech company successfully raises further venture capital in a Series A financing. The funds will be used for the expansion of its production capacity and the extension of its distribution network. JeNaCell is a specialist for biotechnologically produced nanocellulose and has developed a unique continuous manufacturing process.. A seed financing round in 2012 with the High-Tech Gruenderfonds (HTGF) and the Foundation for Technology, Innovation and Research of Thuringia (STIFT) allow
12. October 2012
JeNaCell Receives Seed Financing from High-Tech Gründerfonds and STIFT
High-Tech Gründerfonds and STIFT are jointly investing €700,000 in JeNaCell GmbH. The capital will be used to build up automated production in the creation of a high-performance, high-tech biomaterial. The business idea of JeNaCell GmbH, a spin-off of the Friedrich Schiller University in Jena, Germany, is based on a new and patented process for the continuous production of a high-performance biomaterial with natural nanostructures, which can be used for making innovative medical and cos

Info & Contact

PD Dr. Dana Kralisch


JeNaCell GmbH
Göschwitzer Str. 22
D-07745 Jena

In portfolio

14. Sep 2012 – 02. Aug 2021


HTGF Manager

Dr. Martin Pfister, Principal / Authorized Signatory